Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis

[1]  A. Inno,et al.  PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology , 2023, Cancers.

[2]  E. Nagel,et al.  Native T1 is predictive of cardiovascular death/heart failure events and all-cause mortality irrespective of the patient’s volume status , 2023, Frontiers in Cardiovascular Medicine.

[3]  Jiamin Xu,et al.  Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation , 2023, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  A. Barbieri,et al.  Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways , 2022, Frontiers in Cardiovascular Medicine.

[5]  R. Blankstein,et al.  Prognostic Value of T1 Mapping and Feature Tracking by Cardiac Magnetic Resonance in Patients With Signs and Symptoms Suspecting Heart Failure and No Clinical Evidence of Coronary Artery Disease , 2022, Journal of the American Heart Association.

[6]  I. Kardys,et al.  Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors , 2021, JACC. CardioOncology.

[7]  G. Adam,et al.  Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy–related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT , 2021, European Radiology.

[8]  G. Biglino,et al.  Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction. , 2021, International journal of cardiology.

[9]  D. Eisenstat,et al.  Resveratrol reduces cardiac NLRP3‐inflammasome activation and systemic inflammation to lessen doxorubicin‐induced cardiotoxicity in juvenile mice , 2021, FEBS letters.

[10]  K. Werys,et al.  Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines , 2021, BMC Cardiovascular Disorders.

[11]  L. Altucci,et al.  The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , 2021, Cardiovascular Diabetology.

[12]  Richard B. Thompson,et al.  Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[13]  F. V. van Leeuwen,et al.  Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients , 2020, Journal of the National Cancer Institute.

[14]  J. Dyck,et al.  The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin , 2020, Archives of Toxicology.

[15]  Richard B. Thompson,et al.  Aerobic Fitness Is Related to Myocardial Fibrosis Post–Anthracycline Therapy , 2020, Medicine and science in sports and exercise.

[16]  En-Sheng Ji,et al.  Resveratrol protects against CIH-induced myocardial injury by targeting Nrf2 and blocking NLRP3 inflammasome activation. , 2020, Life sciences.

[17]  Paul Yip,et al.  Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. , 2019, JACC. Cardiovascular imaging.

[18]  S. Loi,et al.  Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain , 2019, JACC. CardioOncology.

[19]  Jian Sun,et al.  Resveratrol attenuates pulmonary embolism associated cardiac injury by suppressing activation of the inflammasome via the MALAT1‑miR‑22‑3p signaling pathway. , 2019, International journal of molecular medicine.

[20]  A. Cohen-Solal,et al.  Subclinical Left Ventricular Dysfunction During Chemotherapy , 2018, Cardiac failure review.

[21]  A. El-Kadi,et al.  The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity , 2018, Cardiovascular Toxicology.

[22]  F. von Knobelsdorff-Brenkenhoff,et al.  Native myocardial T1 time can predict development of subsequent anthracycline‐induced cardiomyopathy , 2018, ESC heart failure.

[23]  L. Badano,et al.  The Good, the Bad, and the Ugly of Using Left Ventricular Longitudinal Myocardial Deformation by Speckle-Tracking Echocardiography to Assess Patients After an Acute Myocardial Infarction , 2017, Circulation. Cardiovascular imaging.

[24]  W. Hundley,et al.  Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy. , 2017, JACC. Cardiovascular imaging.

[25]  W. Hundley,et al.  Is Myocardial Fibrosis a New Frontier for Discovery in Cardiotoxicity Related to the Administration of Anthracyclines? , 2016, Circulation. Cardiovascular imaging.

[26]  Jennifer H. Jordan,et al.  Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors , 2016, Circulation. Cardiovascular imaging.

[27]  Jun Yang,et al.  Resveratrol pretreatment protects rat hearts from ischemia/reperfusion injury partly via a NALP3 inflammasome pathway. , 2015, International journal of clinical and experimental pathology.

[28]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[29]  Denisa Muraru,et al.  Normal left ventricular mechanics by two-dimensional speckle-tracking echocardiography. Reference values in healthy adults. , 2014, Revista espanola de cardiologia.

[30]  C. Jellis,et al.  Myocardial T1 mapping: modalities and clinical applications. , 2013, Cardiovascular diagnosis and therapy.

[31]  M. Robson,et al.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[32]  O. Simonetti,et al.  Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 Mapping , 2012, Circulation. Cardiovascular imaging.

[33]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[34]  J. Mackey,et al.  Early breast cancer therapy and cardiovascular injury. , 2007, Journal of the American College of Cardiology.

[35]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[37]  T. E. Davis,et al.  Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. , 1979, Cancer treatment reports.